好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Translating the Effects of CMT2S Variants with Human-on-a-chip Neuromuscular Junction Systems
Neuromuscular and Clinical Neurophysiology (EMG)
P2 - Poster Session 2 (11:45 AM-12:45 PM)
11-014
To characterize the neuromuscular phenotype of a specific Charcot-Marie-Tooth disease Type 2S (CMT2S) patient by analyzing the morphology and physiology of diseased motor neurons (MNs) compared to healthy MNs and their subsequent neuromuscular junction (NMJ) differences. 

CMT2S is a rare Charcot-Marie-Tooth disease subtype caused by immunoglobulin mu-binding protein 2 (IGHMBP2) variants that result in abnormal RNA processing leading to alpha-motor neuron degeneration. A patient was reported with variants within IGHMBP2. Whole genome sequencing revealed a paternally inherited cryptic splice site non-coding variant (c.1235+894 C>A) in intron 8, which leads to nonsense-mediated decay resulting in IGHMBP2 haploinsufficiency.

CMT2S-MNs were differentiated from an iPSC cell line generated from the patient’s fibroblasts. Patch clamp electrophysiology, phase imaging, and immunocytochemistry experiments were performed to characterize CMT2S-MNs and identify morphology differences. To determine NMJ defects, CMT2S-MNs and control iPSCs (WT-MNs) were integrated into a dual-chamber NMJ platform with wild-type iPSC-derived skeletal muscle myofibers.

Patch clamp electrophysiology revealed hyperexcitability and spontaneous firing of CMT2S-MNs. Similar characteristics can be found in amyotrophic lateral sclerosis-derived MNs (ALS-MNs), though ALS-MNs show hyperexcitability much later than CMT2S-MNs. Analysis of Na+ current normalized by membrane capacitance showed a significant decrease in membrane capacitance and membrane potential in CMT2S-MNs compared to WT-MNs. An NMJ fatigue index (FI) functional readout revealed low FI and quick fatigue in CMT2S. The CMT2S NMJ system presented a dominant phenotype of tetanus, followed by decay.

CMT2S-MNs revealed a hyperexcitable phenotype with spontaneous firing, comparable to amyotrophic lateral sclerosis. The hyperexcitability observed in CMT2S-MNs may be caused by the observed reduced resting membrane potential, reduced membrane capacitance, and thus reduced Na+ current density. NMJ FI showed quick fatigue which may correlate with a CMT2S clinical phenotype. We are further analyzing this patient-specific model to continue phenotyping CMT2S caused by IGHMBP2 variants.

Authors/Disclosures
Caroline Johnson (Vanda Pharmaceuticals Inc.)
PRESENTER
Caroline Johnson has received personal compensation for serving as an employee of Vanda Pharmaceuticals, Inc.. Caroline Johnson has stock in Vanda Pharmaceuticals, Inc..
Sandra Smieszek (VANDA) Dr. Smieszek has received personal compensation for serving as an employee of Vanda Pharmaceuticals Inc.. Dr. Smieszek has stock in Vanda Pharmaceuticals Inc..
Bart Przychodzen No disclosure on file
Christina Tyner (Vanda Pharmaceuticals Inc.) Christina Tyner has received personal compensation for serving as an employee of Vanda Pharmaceuticals Inc. Christina Tyner has or had stock in Vanda Pharmaceuticals Inc..
Christos Polymeropoulos No disclosure on file
Gunther Birznieks (VandaPharma) Gunther Birznieks has received personal compensation for serving as an employee of Vanda Pharmaceuticals. Gunther Birznieks has received intellectual property interests from a discovery or technology relating to health care.
David Hagan (Hesperos) David Hagan has received personal compensation for serving as an employee of Hesperos, Inc. David Hagan has stock in Hesperos, Inc.
Leticia Lenkiu No disclosure on file
Caitlyn Niccum (Hesperos) Caitlyn Niccum has received personal compensation for serving as an employee of Hesperos.
Heather Cannon-Patron (Hesperos, Inc.) Heather Cannon-Patron has received personal compensation for serving as an employee of Hesperos Inc.. Heather Cannon-Patron has stock in Hesperos Inc..
Rocky Brighton (Hesperos inc.) Rocky Brighton has nothing to disclose.
Xiufang Guo The institution of Xiufang Guo has received research support from NIH. The institution of Xiufang Guo has received research support from UCF/Office of Research & Comercialization/Florida High Tech Corridor Council (FHTCC) .
Kenneth Hawkins (Hickman Hybrid Systems Lab) No disclosure on file
Nesar Akanda No disclosure on file
James Hickman (Hesperos, Inc.) James Hickman has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Hesperos, Inc.. James Hickman has stock in Hesperos, Inc.. The institution of James Hickman has received research support from Hesperos, Inc.. James Hickman has received intellectual property interests from a discovery or technology relating to health care. James Hickman has a non-compensated relationship as a Chief Scientist with Hesperos, Inc. that is relevant to AAN interests or activities.
Mihael Polymeropoulos Mihael Polymeropoulos has received personal compensation for serving as an employee of Vanda Pharmaceuticals . Mihael Polymeropoulos has received personal compensation for serving as an employee of Vanda Pharmaceuticals . Mihael Polymeropoulos has stock in Vanda Pharmaceuticals .